LMP7 Antibody (D-2): sc-374089

LMP7 Antibody (D-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects LMP7 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). LMP7 Antibody (D-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. LMP7 plays a crucial role in the immune response as a component of the proteasome, a multi-catalytic proteinase complex located in both the nucleus and cytoplasm of cells. This complex is essential for the degradation of ubiquitinated proteins, thereby regulating various cellular processes, including the presentation of antigens to cytotoxic T cells. LMP7, along with LMP2, is involved in the replacement of standard proteasome subunits with immunoproteasome subunits upon stimulation with interferon-gamma, enhancing the generation of peptides that are presented by MHC class I molecules. This process is vital for the activation of cytotoxic T lymphocytes, which are crucial for the adaptive immune response. LMP7 is expressed in two forms, LMP7A and LMP7B, which are produced as precursor proteins that undergo processing to form active subunits capable of integrating into the proteasome. The ability of LMP7 to modulate the proteasome′s function highlights its importance in immune surveillance and response, making anti-LMP7 antibody (D-2) a valuable tool for studying immune-related processes in various research applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

LMP7 Antibody (D-2) References:

1. IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome.  |  Namiki, S., et al. 2005. FEBS Lett. 579: 2781-7. PMID: 15907481
2. Ablation and Inhibition of the Immunoproteasome Catalytic Subunit LMP7 Attenuate Experimental Abdominal Aortic Aneurysm Formation in Mice.  |  Li, FD., et al. 2019. J Immunol. 202: 1176-1185. PMID: 30642978
3. The genetic association between LMP2 and LMP7 polymorphisms and susceptibility of insulin dependent diabetes mellitus: A meta-analysis.  |  Xu, Y., et al. 2020. Medicine (Baltimore). 99: e19482. PMID: 32221071
4. HIV-1 Nef Interacts with LMP7 To Attenuate Immunoproteasome Formation and Major Histocompatibility Complex Class I Antigen Presentation.  |  Yang, Y., et al. 2020. mBio. 11: PMID: 33109760
5. M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models.  |  Sanderson, MP., et al. 2021. Mol Cancer Ther. 20: 1378-1387. PMID: 34045234
6. Emodin alleviates high glucose-induced oxidative stress, inflammation and extracellular matrix accumulation of mesangial cells by the circ_0000064/miR-30c-5p/Lmp7 axis.  |  Sun, L., et al. 2022. J Recept Signal Transduct Res. 42: 302-312. PMID: 34151713
7. Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).  |  Klein, M., et al. 2021. J Med Chem. 64: 10230-10245. PMID: 34228444
8. Inhibition of the Immunoproteasome Subunit LMP7 Ameliorates Cerebral White Matter Demyelination Possibly via TGFβ/Smad Signaling.  |  Chen, X., et al. 2021. Evid Based Complement Alternat Med. 2021: 6426225. PMID: 34675988
9. The major histocompatibility complex-encoded proteasome component LMP7: alternative first exons and post-translational processing.  |  Glynne, R., et al. 1993. Eur J Immunol. 23: 860-6. PMID: 8458375

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-LMP7 Antibody (D-2) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-LMP7 Antibody (D-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

LMP7 Antibody (D-2) Specifications

Alternate Product Name: LMP7

Product Clone Name: D-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 229-268

Epitope Target: LMP7

Epitope Species: human

Product Reactivity/Detection: LMP7A and LMP7B

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for LMP7 Antibody (D-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred LMP7 antibody is LMP7 Antibody (A-12): sc-365699.